-
Mashup Score: 5
We propose that GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing’s syndrome results from a two-hit inactivation of KDM1A, consistent with the tumour suppressor gene model of tumorigenesis. Genetic testing and counselling should be offered to these patients and their relatives.
Categories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 3
We propose that GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing’s syndrome results from a two-hit inactivation of KDM1A, consistent with the tumour suppressor gene model of tumorigenesis. Genetic testing and counselling should be offered to these patients and their relatives.
Categories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 2
We propose that GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing’s syndrome results from a two-hit inactivation of KDM1A, consistent with the tumour suppressor gene model of tumorigenesis. Genetic testing and counselling should be offered to these patients and their relatives.
Categories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 4
We propose that GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing’s syndrome results from a two-hit inactivation of KDM1A, consistent with the tumour suppressor gene model of tumorigenesis. Genetic testing and counselling should be offered to these patients and their relatives.
Categories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 5
Tirzepatide showed robust improvements in glycaemic control and bodyweight, without increased risk of hypoglycaemia. The safety profile was consistent with GLP-1 receptor agonists, indicating a potential monotherapy use of tirzepatide for type 2 diabetes treatment.
Source: The LancetCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0GIPR function in the CNS: implications and novel perspectives for GIP-based therapies in treating metabolic disorders - 3 year(s) ago
During the past decade, pharmaceutical engineering of unimolecular agents has revealed the therapeutic potential of glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism. From this work, one of the most intriguing findings is that engagement of GIPR enhances the weight loss profile of glucagon-like peptide-1 (GLP-1) based therapeutics. Consequently, this pharmacological approach,…
Source: DiabetesCategories: Healthcare Professionals, Latest HeadlinesTweet
Online—Loss of #KDM1A in #GIP-dependent primary bilateral macronodular #adrenal hyperplasia with #Cushing's syndrome: a multicentre, retrospective, cohort study https://t.co/M55SCFsMI7 #PBMAH #genetics https://t.co/LfIC84UAps